Navigation Links
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Date:2/27/2008

- Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus

- Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of

mTOR - Results of RECORD-1 trial address unmet medical need in renal cell cancer

with worldwide regulatory filings planned for second half of 2008

- Complete results to be submitted as late-breaking abstract for

presentation at the American Society of Clinical Oncology meeting

EAST HANOVER, N.J., Feb. 28 /PRNewswire-FirstCall/ -- An independent data monitoring committee stopped a major Phase III clinical trial of the investigational drug everolimus (RAD001) today after interim results showed significantly better progression-free survival in patients with advanced kidney cancer who received everolimus compared to placebo.

The committee stopped the trial of more than 400 patients conducted in 12 countries because the study met its primary endpoint. The interim findings are being shared with investigators to allow them to offer everolimus to patients remaining on placebo. Everolimus may fulfill an unmet medical need for patients with advanced renal cell cancer (RCC) who currently have no approved treatment options.

Everolimus is a once-daily oral therapy that offers a new approach to cancer treatment by inhibiting the mTOR protein, a central regulator of tumor cell division and blood vessel growth in cancer cells. The trial included patients who had their cancer worsen despite receiving approved treatments for RCC, such as Nexavar(R) (sorafenib)(1) or Sutent(R) (sunitinib)(2) or both. In addition, prior therapy with Avastin(R) (bevacizumab)(3) and interferon was allowed.

"Everolimus has the potential to greatly help patients with kidney cancer, especially in advanced stage who up to now
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
5. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
6. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
7. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
10. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...wire/ -- Radiologists can accurately diagnose acut... of a handheld device or mobile phone equipped wit... today at the annual meeting of the Radiological S...s to improve the speed and accuracy of medical dia... different consulting physicians," said the study,...
(Date:11/29/2009)...wire/ -- A large proportion of patients who underg...e unindicated and unnecessary additional image acq...exposure, according to a study presented today at ...North America (RSNA). ,, "It is the responsibil...tion to ensure that the dosage is as low as reason...
(Date:11/29/2009)...Newswire/ -- Royal Philips Electronics ( PHG, AEX:...need by showing its portfolio of products designed...al meeting of the Radiological Society of North Am...ps are several advancements and upgrades focused o...streamlining workflow to expand upon clinical capa...
Breaking Medicine Technology:Smart Phones Allow Quick Diagnosis of Acute Appendicitis 2Smart Phones Allow Quick Diagnosis of Acute Appendicitis 3Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 2Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 3Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 2Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 3Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 4Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 5Toyota Awards 241 Million in Scholarships to 100 High School Seniors Roslyn Highs Urbach Named One of Only 12 National Winners 3B Receives 2420 00 49712 1Toyota Awards 241 Million in Scholarships to 100 High School Seniors Roslyn Highs Urbach Named One of Only 12 National Winners 3B Receives 2420 00 49712 2Toyota Awards 241 Million in Scholarships to 100 High School Seniors Roslyn Highs Urbach Named One of Only 12 National Winners 3B Receives 2420 00 49712 3AFFiRiS AG 3A 1st Place in Venture Capital 26 Private Equity Awards for MIG Fonds and AFFiRiS 12736 1AFFiRiS AG 3A 1st Place in Venture Capital 26 Private Equity Awards for MIG Fonds and AFFiRiS 12736 2AFFiRiS AG 3A 1st Place in Venture Capital 26 Private Equity Awards for MIG Fonds and AFFiRiS 12736 3Lumension Audiocast With Aberdeen Group Highlights How to Reduce IT Costs By Effectively Managing and Securing Endpoints 49709 1Lumension Audiocast With Aberdeen Group Highlights How to Reduce IT Costs By Effectively Managing and Securing Endpoints 49709 2Lumension Audiocast With Aberdeen Group Highlights How to Reduce IT Costs By Effectively Managing and Securing Endpoints 49709 3
...TA, Sept. 24 Alimera Sciences, Inc., a privately,... the research,development and commercialization of...ported that after completing its review of safety,...ent Data Safety,Monitoring Board (DSMB) has again ...trials for the use of Iluvien(TM) in the treatment...
...OLIS, Md., Sept. 24 PharmAthene, Inc.,(Amex: PIP...rmeasures,against biological and chemical threats,...o posters and an oral presentation on its medical,...Valortim(R) at the HHS,Public Health Emergency Med...ers Workshop 2008 / BARDA Industry Day being held ...
Other Medicine Technology:DSMB Again Supports Continuation of Alimera Sciences' Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME 2DSMB Again Supports Continuation of Alimera Sciences' Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME 3PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 7
(Date:11/29/2009)... Moravia,s Nanjing-based Service Delivery ... , Brno, Czech Republic (...on solution provider, is pleased to announce its p...009, to be held in Nanjing, China, on November 30,...ion-based companies that have established and grow...
(Date:11/29/2009)...ng mannequins to teach doctors-in-training how to ...y to improve their skills without compromising pat...m Henry Ford Hospital. , The study shows that th...ble tool to improve medical residents, knowledge, ...e more common ultrasound-guided procedures, includ...
(Date:11/29/2009)...e get blamed for something leads to more self-defe...UNDAY, Nov. 29 (HealthDay News) -- The blame game ...n the target is innocent. , Researchers found t... a problem, even if it,s an unfair accusation, the... too. , "When we see others protecting their e...
(Date:11/29/2009)... "The YogaForce A-Line Athletic Mat i...Andrew Weil, M.D., author and physician best known...tegrative medicine. Go to www.yogaforce.com and... the gift list. , San Fra...me for the holidays, the YogaForce newly patented,...
(Date:11/28/2009)...CAGO, Nov. 28 Get ready for adv...he clinical routine when Siemens introduces ... and Annual Meeting of the Radiological Society of... 3 at McCormick Place (Booth #825, East Building/L... via , Siemens, new imaging software for mult...
Breaking Medicine News(10 mins):Health News:Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China 2Health News:Simulated training for ultrasound-guided procedures improves safety without risk to patients 2Health News:When Accusations Start to Fly, They Multiply 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5
...Topp Twins, well known entertainment duo, has been...pp, 48, one of the duo with her sister Lynda, is r...erapy treatment during the next few weeks. Topp... breast lumps checked immediately and her prompt a...
...lled Rosiglitazone capable of controlling Type 2 d...hers, Researchers// content that this drug is capa...h medical journal . Researchers content that this ...ion )conducted at Royal Victoria Hospital led by e...
...a recent study, kids with bigger heads tend to be ... This study conducted by Catherine Gale, Ph.D....ssue of the journal Pediatrics. 633 full-term ...4 and 8years. The kids took IQ tests at the ...
... prevention office of the Ministry of Health relea... Blind, according to which//, around 45,000 new ca...ina. "By July, China has reported 12 million p...office in East China's Shandong Province. Acco...
...rage commercial banking of umbilical cord blood. O...e to public// blood banks without the motive of fi...th stem cells are beneficial in treating diseases ...ely easy to obtain. Also cord blood is not known t...
...rus appears to be fast engulfing Uttar Pradesh's c...ay. "Of the 31 dengue-positive cases admitted... affected districts,// 20 were from Lucknow alone,... past four days, taking the tally to 97 in Lucknow...
Other Medicine News:Health News:New drug proven to tackle Type 2 Diabetes 2Health News:Baby’s Head Growth influences its Intelligence 2Health News:NHS Will Do Well to Curb Use Of Umbilical Cord Blood For Treatment of Cancers 2
...NS272 is a fully featured Peripheral Nerve Stimula...omuscular blocks during surgery or intensive care ...anesthesia. , ,The constant current NS232, NS252,...rammed. ,Hand-held, battery operated, and includes...
EZStim™II
TR 5000 Tourniquet Systems
TR 4500 Tourniquet Systems
Medicine Products: